z-logo
open-access-imgOpen Access
Idiopathic basal ganglia calcification‐associated PDGFRB mutations impair the receptor signalling
Author(s) -
Arts Florence A.,
Velghe Amélie I.,
Stevens Monique,
Renauld JeanChristophe,
Essaghir Ahmed,
Demoulin JeanBaptiste
Publication year - 2015
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.12443
Subject(s) - pdgfrb , biology , platelet derived growth factor receptor , cancer research , pdgfb , pdgfra , microbiology and biotechnology , receptor , genetics , growth factor , gene , gist , stromal cell
Abstract Platelet‐derived growth factors ( PDGF ) bind to two related receptor tyrosine kinases, which are encoded by the PDGFRA and PDGFRB genes. Recently, heterozygous PDGFRB mutations have been described in patients diagnosed with idiopathic basal ganglia calcification ( IBGC or Fahr disease), a rare inherited neurological disorder. The goal of the present study was to determine whether these mutations had a positive or negative impact on the PDGFRB activity. We first showed that the E1071V mutant behaved like wild‐type PDGFRB and may represent a polymorphism unrelated to IBGC . In contrast, the L658P mutant had no kinase activity and failed to activate any of the pathways normally stimulated by PDGF . The R987W mutant activated Akt and MAP kinases but did not induce the phosphorylation of signal transducer and activator of transcription 3 ( STAT 3) after PDGF stimulation. Phosphorylation of phospholipase Cγ was also decreased. Finally, we showed that the R987W mutant was more rapidly degraded upon PDGF binding compared to wild‐type PDGFRB . In conclusion, PDGFRB mutations associated with IBGC impair the receptor signalling. PDGFRB loss of function in IBGC is consistent with recently described inactivating mutations in the PDGF ‐B ligand. These results raise concerns about the long‐term safety of PDGF receptor inhibition by drugs such as imatinib.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here